Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis - PubMed (original) (raw)
Affiliations
- PMID: 12610804
Clinical Trial
Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis
Jun Hasegawa et al. J Rheumatol. 2003 Mar.
Abstract
Objective: Osteoclast activation or cartilage and bone destruction are developed in patients with rheumatoid arthritis (RA). The efficacy of etidronate with respect to osteoporosis, inhibition of bone resorption and destruction, and antiinflammation in RA was examined for 72 weeks.
Methods: Sixty-three patients with RA (56 women, 7 men) were divided into a group that received intermittent cyclical etidronate therapy (ICET) (31 patients) and a non-ICET group (32 patients). Over a 72 week followup period, the urinary deoxypyridinoline (DPD), serum bone alkaline phosphatase (BAP), bone mineral density (BMD), Larsen damage score, Lansbury activity index, and concentrations of serum C-reactive protein (CRP) and serum interleukin 6 (IL-6) of the 2 groups were compared.
Results: In the non-ICET group, a significant decrease in BMD and a significant increase in the Larsen damage score were observed. In the ICET group, the level of DPD started to decrease 12 weeks after etidronate administration and progression of the Larsen damage score was significantly inhibited. IL-6 concentration was significantly decreased 72 weeks after etidronate administration. Concentrations of BAP and CRP and the Lansbury activity index were not significantly different between the ICET and the non-ICET groups. A significant correlation between the IL-6 and DPD concentrations was observed.
Conclusion: Etidronate was effective at inhibiting bone resorption and destruction in study patients with RA, while not increasing BAP concentrations; and a correlation was observed between the concentration of DPD and IL-6, indicating the antiinflammatory effect of etidronate.
Similar articles
- Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models.
Yamamoto K, Yoshino S, Shue G, Nagashima M. Yamamoto K, et al. Rheumatol Int. 2006 May;26(7):627-32. doi: 10.1007/s00296-005-0042-y. Epub 2005 Aug 27. Rheumatol Int. 2006. PMID: 16133581 - Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Morishita M, Nagashima M, Wauke K, Takahashi H, Takenouchi K. Morishita M, et al. J Rheumatol. 2008 Mar;35(3):407-13. Epub 2008 Feb 1. J Rheumatol. 2008. PMID: 18260178 Clinical Trial. - [Biological effects of bisphosphonates in patients with rheumatoid arthritis].
Nagashima M, Shu G, Yamamoto K. Nagashima M, et al. Nihon Rinsho. 2005 Sep;63(9):1607-12. Nihon Rinsho. 2005. PMID: 16164219 Review. Japanese. - Efficacy of oral etidronate for skeletal diseases in Japan.
Iwamoto J, Takeda T, Sato Y. Iwamoto J, et al. Yonsei Med J. 2005 Jun 30;46(3):313-20. doi: 10.3349/ymj.2005.46.3.313. Yonsei Med J. 2005. PMID: 15988801 Free PMC article. Retracted. Review.
Cited by
- Effect of neridronate on axial involvement in patients with spondyloarthritis when biologics are not possible. Results of a monocentric study.
Crotti C, Di Taranto R, Orsini F, Ferrito M, Varenna M, Favalli EG, Caporali R. Crotti C, et al. Front Med (Lausanne). 2023 Nov 20;10:1282169. doi: 10.3389/fmed.2023.1282169. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38076262 Free PMC article. - Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis.
Jochems C, Lagerquist M, Håkansson C, Ohlsson C, Carlsten H. Jochems C, et al. Clin Exp Immunol. 2008 Jun;152(3):593-7. doi: 10.1111/j.1365-2249.2008.03660.x. Epub 2008 Apr 24. Clin Exp Immunol. 2008. PMID: 18435803 Free PMC article. - Inhibitory effect of bone resorption and inflammation with etidronate therapy in patients with rheumatoid arthritis for 3 years and in vitro assay in arthritis models.
Yamamoto K, Yoshino S, Shue G, Nagashima M. Yamamoto K, et al. Rheumatol Int. 2006 May;26(7):627-32. doi: 10.1007/s00296-005-0042-y. Epub 2005 Aug 27. Rheumatol Int. 2006. PMID: 16133581 - Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456].
Forsblad d'Elia H, Christgau S, Mattsson LA, Saxne T, Ohlsson C, Nordborg E, Carlsten H. Forsblad d'Elia H, et al. Arthritis Res Ther. 2004;6(5):R457-68. doi: 10.1186/ar1215. Epub 2004 Aug 6. Arthritis Res Ther. 2004. PMID: 15380045 Free PMC article. Clinical Trial. - Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options.
Toussirot E, Wendling D. Toussirot E, et al. Drugs Aging. 2005;22(6):451-69. doi: 10.2165/00002512-200522060-00001. Drugs Aging. 2005. PMID: 15974637 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous